Optimizing Bicycle Drug Conjugate Dosage Using Exposure-Response Data

• Developing Pop-PK and Exposure-Response models to identify patient characteristics that could impact PK of Bicycle Drug Conjugates® (BDC)
• Integrating PK, efficacy, and safety data to characterise risk-benefit profile and identify optimal dosing strategies
• Establishing a modelling platform to support BDC® decision making in drug development

Speakers: